• Subject must be age ≥18 years of age, at the time of signing the informed consent.

• Chronic non-ischemic cardiomyopathy

• 15% ≤ LVEF ≤ 35% by transthoracic echocardiography (TTE) at screening

• 6MWT \>50 meters

• Medically stable, NYHA Class III HF for a minimum of 4 weeks while on appropriate medical therapy (defined below) including, but not limited to:

∙ Beta blocker therapy and ACE inhibitor or angiotensin receptor blocker (ARB) or sacubitril/valsartan combination therapy (Entresto) for ≥ 90 days prior to enrollment.

∙ May also receive aldosterone antagonist therapy. Doses of the above medications must be stable for ≥ 30 days prior to enrollment; and

‣ Cardiac resynchronization therapy (Zareba et al 2011), if clinically indicated, must have been implanted ≥ 90 days prior to enrollment. Internal cardioverter defibrillator (ICD) must be implanted, if clinically indicated ≥ 30 days prior to enrollment.

• Women of childbearing potential must use at least one of the following acceptable birth control methods throughout the study and for 6 months after IP administration:

‣ Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum prior to IP administration

⁃ Intrauterine device in place for at least 90 days prior to receiving IP

⁃ Barrier methods (diaphragm plus spermicide or condom) starting at least 30 days prior to receiving IP

⁃ Abstinence (the subject must be willing to remain abstinent from screening to 6 months after receiving IP). Females are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject

⁃ Surgical sterilization of the partner(s) (vasectomy) for \>180 days prior to IP administration

⁃ Hormonal contraceptives starting \> 90 days prior to IP. If hormonal contraceptives are started less than 90 days prior to receiving IP, subjects must agree to use a barrier method (diaphragm plus spermicide or condom) from screening through 90 days after initiation of hormonal contraceptives

• Males subjects capable of fathering a child:

‣ Must agree to use a condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant from IP administration through 6 months after the time of IP administration

⁃ Must agree not to donate sperm for 6 months after time of receiving IP

⁃ Documented evidence of vasectomy in males for 180 days minimum prior to receiving IP is an acceptable form of contraception

⁃ Males who claim abstinence as their method of contraception are allowed, provided they agree to use barrier methods should they become sexually active from screening through 6 months after receiving IP. Males are allowed to claim abstinence as their method of contraception only when it is the preferred and usual lifestyle of the subject

• Appropriate candidate for protocol-specified intracoronary infusion in the judgment of the infusing interventional cardiologist